Adage Capital Partners
AIMT

Adage Capital Partners’s Aimmune Therapeutics AIMT Stock Holding History

Adage Capital Partners’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-400,000
Closed -$8.94M – 781
2019
Q1 		$8.94M Hold
400,000
– – 0.02% 542
2018
Q4 		$9.57M Buy
+400,000
New +$10.4M 0.03% 515
2018
Q2 		– Sell
-550,000
Closed -$17.5M – 813
2018
Q1 		$17.5M Sell
550,000
-750,000
-58% -$26.4M 0.04% 430
2017
Q4 		$49.2M Sell
1,300,000
-313,452
-19% -$10.1M 0.11% 226
2017
Q3 		$40M Sell
1,613,452
-286,548
-15% -$6.18M 0.1% 261
2017
Q2 		$39.1M Buy
1,900,000
+658,600
+53% +$12.6M 0.1% 274
2017
Q1 		$27M Buy
1,241,400
+100,000
+9% +$2.05M 0.07% 343
2016
Q4 		$23.3M Buy
1,141,400
+25,000
+2% +$511K 0.06% 339
2016
Q3 		$16.7M Hold
1,116,400
– – 0.05% 414
2016
Q2 		$12.1M Sell
1,116,400
-25,000
-2% -$340K 0.03% 475
2016
Q1 		$15.5M Hold
1,141,400
– – 0.04% 421
2015
Q4 		$21.1M Sell
1,141,400
-100,000
-8% -$1.85M 0.06% 360
2015
Q3 		$31.4M Buy
+1,241,400
New +$29M 0.09% 292

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's AIMT Position: Q2 2019 in Review

Adage Capital Partners sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 400,000 shares — an estimated $8.94M sold.

Adage Capital Partners first reported a position in AIMT in Q3 2015 and held it in 13 quarters. The position peaked at $49.2M in Q4 2017. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • Adage Capital Partners reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Adage Capital Partners sold 400,000 Aimmune Therapeutics shares in Q2 2019, an estimated $8.94M.
  • Adage Capital Partners first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 13 quarters.
  • Adage Capital Partners's Aimmune Therapeutics position peaked at $49.2M in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Adage Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.